Cargando…

Patterns of care in the management of high-risk COPD in the US (2011–2019): an observational study for the CONQUEST quality improvement program

BACKGROUND: In this study, we compare management of patients with high-risk chronic obstructive pulmonary disease (COPD) in the United States to national and international guidelines and quality standards, including the COllaboratioN on QUality improvement initiative for achieving Excellence in STan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerr, Margee, Tarabichi, Yasir, Evans, Alexander, Mapel, Douglas, Pace, Wilson, Carter, Victoria, Couper, Amy, Drummond, M. Bradley, Feigler, Norbert, Federman, Alex, Gandhi, Hitesh, Hanania, Nicola A., Kaplan, Alan, Kostikas, Konstantinos, Kruszyk, Maja, van Melle, Marije, Müllerová, Hana, Murray, Ruth, Ohar, Jill, Pollack, Michael, Pullen, Rachel, Williams, Dennis, Wisnivesky, Juan, Han, MeiLan K., Meldrum, Catherine, Price, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400879/
https://www.ncbi.nlm.nih.gov/pubmed/37545746
http://dx.doi.org/10.1016/j.lana.2023.100546
Descripción
Sumario:BACKGROUND: In this study, we compare management of patients with high-risk chronic obstructive pulmonary disease (COPD) in the United States to national and international guidelines and quality standards, including the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST). METHODS: Patients were identified from the DARTNet Practice Performance Registry and categorized into three high-risk cohorts in each year from 2011 to 2019: newly diagnosed (≤12 months after diagnosis), already diagnosed, and patients with potential undiagnosed COPD. Patients were considered high-risk if they had a history of exacerbations or likely exacerbations (respiratory consult with prescribed medication). Descriptive statistics for 2019 are reported, along with annual trends. FINDINGS: In 2019, 10% (n = 16,610/167,197) of patients met high-risk criteria. Evidence of spirometry for diagnosis was low; in 2019, 81% (n = 1228/1523) of patients newly diagnosed at high-risk had no record of spirometry/peak expiratory flow in the 12 months pre- or post-diagnosis and 43% (n = 651/1523) had no record of COPD symptom review. Among those newly and already diagnosed at high-risk, 52% (n = 4830/9350) had no evidence of COPD medication. INTERPRETATION: Findings suggest inconsistent adherence to evidence-based guidelines, and opportunities to improve identification, documentation of services, assessment, therapeutic intervention, and follow-up of patients with COPD. FUNDING: This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global and 10.13039/100004325AstraZeneca Ltd. No funding was received by the Observational & Pragmatic Research Institute Pte Ltd (OPRI) for its contribution.